NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

Ballinrobe Community School celebrated major success at the recent BT Young Scientist and Technology Exhibition held in the ...

ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and olde ...

As the demand for novel therapies and personalized medicine surges, leaders are uniquely positioned to create a culture of creativity, collaboration and innovation.

There are thousands of science societies, so the team decided to focus specifically on ecological and evolution societies. To narrow the data down ... so-called 'research pipeline' that other ...

A 2023 reform has boosted voucher use by 67%, with one-quarter of state scholarships now going to families in the top income ...

Veracyte, Inc. , a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical ...

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

In 2021, it announced it was committing $2 billion over 10 years to accelerate inclusion and equity throughout the academic science pipeline. And it is dashing hopes that deep-pocketed ...

“Building on our data presented at ASH in December ... and have an oral presentation update on the hematotoxicity model and poster presentation on the impact of deep molecular remissions ...